<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716833</url>
  </required_header>
  <id_info>
    <org_study_id>MPC-UM-0002-DI</org_study_id>
    <nct_id>NCT00716833</nct_id>
  </id_info>
  <brief_title>Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery</brief_title>
  <acronym>EPPA</acronym>
  <official_title>Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised placebo controlled double-blinded bicentre study (phase III) was designed to&#xD;
      evaluate the preemptive and postoperative analgetic impact of etoricoxibe in open abdominal&#xD;
      and thoracic surgery. Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme&#xD;
      (COX-2).&#xD;
&#xD;
      Therefore 120 patients (ASA-risk 1-2) with upcoming abdominal or thoracic surgery should be&#xD;
      included into this study. Patients are randomly allocated to either the preemptive or the&#xD;
      postoperative Etoricoxibe group. These two groups are divided each into two arms. Preemptive&#xD;
      group patients get Etoricoxibe either twice (before and after surgery) or just a single&#xD;
      preoperative dose. Postoperative group patients get placebo before surgery and either a drug&#xD;
      application or a placebo again after surgery (so called 2x2 factorial study design).&#xD;
&#xD;
      Cumulative use of morphine as assessed within first 48 hours after surgery is the primary&#xD;
      trial outcome indicating the analgesic potency of Etoricoxibe.&#xD;
&#xD;
      In addition, changes in patients level of sensibilisation will be measured with help of&#xD;
      quantitative sensory testing (a standardised procedure) before and after surgery (secondary&#xD;
      outcome). In addition pharmacogenetic testing will provide information about genetic&#xD;
      aberrations (so called polymorphisms) of the patients enzymes that should be compared to the&#xD;
      individual reaction regarding Etoricoxibe.&#xD;
&#xD;
      The results will give hint about the analgesic impact of etoricoxibe in acute postoperative&#xD;
      pain. There will be findings for preemptive analgesia and nerval processes. All this could&#xD;
      lead to an improvement of postoperative pain relief while administrating preemptively a COX-2&#xD;
      selective inhibitor before surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Etoricoxib (brand name Arcoxia worldwide; also Algix and Tauxib in Italy) is a new COX-2&#xD;
      selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1).&#xD;
      Doses are 120 mg/day for acute pain. Current therapeutic indications are: treatment of&#xD;
      rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute&#xD;
      pain and gout. Note that approved indications differ by country.&#xD;
&#xD;
      Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of&#xD;
      cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from&#xD;
      arachidonic acid. Among the different functions exerted by PGs, their role in the&#xD;
      inflammation cascade should be highlighted. COX-2 selective inhibitor (aka &quot;COXIB&quot;) showed&#xD;
      less marked activity on type 1 cycloxigenase compared to traditional non-steroidal&#xD;
      anti-inflammatory drugs (NSAID). This reduced activity is the cause of reduced&#xD;
      gastrointestinal toxicity.&#xD;
&#xD;
      Quantitative sensory tests (QST) are techniques employed to measure the intensity of stimuli&#xD;
      needed to produce specific sensory perceptions. They are used to evaluate a sensory detection&#xD;
      threshold or other sensory responses from supra-threshold stimulation. The common physical&#xD;
      stimuli are (i) touch-pressure, (ii) vibration, and (iii) coolness, warmth, cold pain, and&#xD;
      heat pain. In QST, the subject must be able to comprehend what is being asked by the test,&#xD;
      alert and not taking mind-altering medications, and not biased to a certain test outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative use of morphine as assessed within first 48 hours after surgery</measure>
    <time_frame>first 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in patients level of sensibilisation will be measured with help of quantitative sensory testing (a standardised procedure) before and after surgery.</measure>
    <time_frame>preoperative and 48h postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic testing will provide information about genetic aberrations (so called polymorphisms) of the patients enzymes that should be compared to the individual reaction regarding Etoricoxibe.</measure>
    <time_frame>48 hours postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Pain</condition>
  <condition>Abdominal Surgery</condition>
  <condition>Thoracic Surgery</condition>
  <arm_group>
    <arm_group_label>Preemptive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxibe</intervention_name>
    <description>Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.</description>
    <arm_group_label>Preemptive</arm_group_label>
    <other_name>Etoricoxibe 120mg Registration-N° 59863.02.00</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).</description>
    <arm_group_label>Postoperative</arm_group_label>
    <other_name>Placebo-Etoricoxibe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Programmed abdominal or thoracic surgery&#xD;
&#xD;
          -  Patients &gt; 18 yrs&#xD;
&#xD;
          -  Patients are aware of German language&#xD;
&#xD;
          -  Participation is voluntary&#xD;
&#xD;
          -  ASA-risk class 1-2 (American Society of Anesthesiologists guidelines)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cardiac, pulmonary, renal or neurologic disease&#xD;
&#xD;
          -  ASA risk III and IV&#xD;
&#xD;
          -  Insulin dependent Diabetes mellitus&#xD;
&#xD;
          -  Polyneuropathy&#xD;
&#xD;
          -  Chronic pain&#xD;
&#xD;
          -  Use of analgesic drugs&#xD;
&#xD;
          -  Ulcus duodeni&#xD;
&#xD;
          -  Ulcus ventriculi&#xD;
&#xD;
          -  Time after intestinal bleeding&#xD;
&#xD;
          -  Allergy reactions towards coxibes or coxibe-like drugs&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Severe hepatic disease (Albumin &lt; 25 g/l or Child-Pugh-Score ≥ 10)&#xD;
&#xD;
          -  Children and Teenager &lt; 16 years&#xD;
&#xD;
          -  Chronic intestinal inflammation&#xD;
&#xD;
          -  Heart failure (NYHA II - IV)&#xD;
&#xD;
          -  Inbalancend arterial hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominik Irnich, PD. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Multidisciplinary Pain Centre, Department of Anaesthesiology, University of Munich, Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Pneumologie und Thoraxchirurgie, Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Klinik und Poliklinik, Innenstadt, Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Fleckenstein J, Kramer S, Offenbächer M, Schober G, Plischke H, Siebeck M, Mussack T, Hatz R, Lehmeyer L, Lang PM, Heindl B, Conzen P, Irnich D. Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols. Trials. 2010 May 27;11:66. doi: 10.1186/1745-6215-11-66.</citation>
    <PMID>20504378</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Dominik Irnich</investigator_full_name>
    <investigator_title>PD Dr. Dominik Irnich</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>coxibe</keyword>
  <keyword>preemptive</keyword>
  <keyword>abdominothoracic</keyword>
  <keyword>sensibilisation</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

